JAMA Oncology:吸烟致癌?颊粘膜拭子一刮就知道!

2015-05-18 MedSci MedSci原创

最新发表在JAMA Oncology杂志上的研究显示,吸烟所引起的DNA损伤可以通过颊粘膜拭子检测到。这项研究为吸烟所导致癌症产生所经历的一般程序提供了证据支持,而这一现象也出现在与吸烟通常被认为没有关联的癌症,包括乳腺癌和妇科癌症。该项由UCL妇女健康协会的妇女肿瘤部主任Martin Widschwendter教授以及伦敦大学的Andrew Teschendorff博士所领导的研究团队着眼于表观

最新发表在JAMA Oncology杂志上的研究显示,吸烟所引起的DNA损伤可以通过颊粘膜拭子检测到。这项研究为吸烟所导致癌症产生所经历的一般程序提供了证据支持,而这一现象也出现在与吸烟通常被认为没有关联的癌症,包括乳腺癌和妇科癌症。

该项由UCL妇女健康协会的妇女肿瘤部主任Martin Widschwendter教授以及伦敦大学的Andrew Teschendorff博士所领导的研究团队着眼于表观遗传改变——开启或关闭基因表达的DNA改变。表观遗传变异与癌症发展密切相关,而前者可能与暴露于香烟烟雾等环境因素相关。

研究人员旨在探索颊粘膜的正常细胞是否会证明表观遗传变化与肺癌和其他上皮癌有关。这些类型的癌症起源于上皮细胞——如皮肤覆盖身体的外面或如粘膜覆盖身体器官和体腔内壁,该类型癌症占英国所有癌症病例的85%。从颊粘膜拭子中很容易收集颊细胞,而后者则直接暴露于吸烟者的香烟烟雾中。

研究人员分析了1946年出生的790名女性的颊粘膜拭子样本以及152例配对的血液样本,该数据来自英国医学研究理事会国家卫生与发展调查委员会。数据集还包含了吸烟史以及收集样本时的吸烟状况。

这一分析表明,吸烟女性的颊粘膜细胞存在很多改变表观基因改变——被称为DNA甲基化(DNAme)。 相比对应的血液样本,吸烟者的颊细胞的异常甲基化会增加40倍,这一差异使它们的DNA变化更可靠。

研究团队接着在5000多个组织样本中分析这种吸烟引起的表观遗传变化过程,包括正常组织、癌前病变组织以及从15个种不同的上皮癌的组织。他们试图在测试过程中区分癌组织和正常组织。他们发现这个发展过程——最初在吸烟者正常颊细胞开始衍生的,能够100%敏感性区分正常和癌组织的,100%特异性出现在发生癌症的器官中。

研究人员还发现,这个变化程序的缺失或存在能够预测前进展性癌症病变的命运。细胞中有缺陷程序的存在很有可能促使前进展性癌症进展到完全进展性癌症。然而,这种缺陷程序的消失则有可能使得癌前病变的发展受抑制,甚至消失。

作者Andrew Teschendorff(伦敦大学癌症研究所)说:“我们的工作表明,吸烟对正常细胞的表观基因组产生重大影响是形同直接暴露于致癌物。具有特别意义的是,这些表观遗传变化也出现与吸烟相关或不想过的癌症中,这意味着是一个普遍的癌症发生过程。这项研究让我们更接近并理解第一步骤致癌作用,以及在未来可能会为我们提供急需的风险预测和早期检测手段。”


原始出处:
Andrew E. Teschendorff, Zhen Yang, Andrew Wong, Christodoulos P. Pipinikas, Yinming Jiao, Allison Jones, Shahzia Anjum, Rebecca Hardy, Helga B. Salvesen, Christina Thirlwell, Samuel M. Janes, Diana Kuh, Martin Widschwendter. Correlation of Smoking-Associated DNA Methylation Changes in Buccal Cells With DNA Methylation Changes in Epithelial Cancer. JAMA Oncology, 2015; DOI:10.1001/jamaoncol.2015.1053

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1820320, encodeId=fb57182032095, content=<a href='/topic/show?id=c6fb1006e830' target=_blank style='color:#2F92EE;'>#颊粘膜拭子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100678, encryptionId=c6fb1006e830, topicName=颊粘膜拭子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69cb413, createdName=chengjn, createdTime=Sat Jul 11 14:55:00 CST 2015, time=2015-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864660, encodeId=c3b118646601c, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Oct 26 22:55:00 CST 2015, time=2015-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1690947, encodeId=4855169094e4f, content=<a href='/topic/show?id=7adce62603e' target=_blank style='color:#2F92EE;'>#粘膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76260, encryptionId=7adce62603e, topicName=粘膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=090129165428, createdName=guoyibin, createdTime=Mon Nov 09 20:55:00 CST 2015, time=2015-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1674368, encodeId=54f416e43680a, content=<a href='/topic/show?id=e8aa13359b1' target=_blank style='color:#2F92EE;'>#Oncology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13359, encryptionId=e8aa13359b1, topicName=Oncology)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb7226973259, createdName=circumcision, createdTime=Sun Aug 30 00:55:00 CST 2015, time=2015-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=24418, encodeId=6b91244187d, content=这么厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b64e106775, createdName=cement123, createdTime=Thu May 21 13:33:00 CST 2015, time=2015-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1370825, encodeId=b6b513e0825ad, content=<a href='/topic/show?id=9c39864991e' target=_blank style='color:#2F92EE;'>#致癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86499, encryptionId=9c39864991e, topicName=致癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c25323, createdName=jambiya, createdTime=Wed May 20 13:55:00 CST 2015, time=2015-05-20, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1820320, encodeId=fb57182032095, content=<a href='/topic/show?id=c6fb1006e830' target=_blank style='color:#2F92EE;'>#颊粘膜拭子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100678, encryptionId=c6fb1006e830, topicName=颊粘膜拭子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69cb413, createdName=chengjn, createdTime=Sat Jul 11 14:55:00 CST 2015, time=2015-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864660, encodeId=c3b118646601c, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Oct 26 22:55:00 CST 2015, time=2015-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1690947, encodeId=4855169094e4f, content=<a href='/topic/show?id=7adce62603e' target=_blank style='color:#2F92EE;'>#粘膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76260, encryptionId=7adce62603e, topicName=粘膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=090129165428, createdName=guoyibin, createdTime=Mon Nov 09 20:55:00 CST 2015, time=2015-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1674368, encodeId=54f416e43680a, content=<a href='/topic/show?id=e8aa13359b1' target=_blank style='color:#2F92EE;'>#Oncology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13359, encryptionId=e8aa13359b1, topicName=Oncology)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb7226973259, createdName=circumcision, createdTime=Sun Aug 30 00:55:00 CST 2015, time=2015-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=24418, encodeId=6b91244187d, content=这么厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b64e106775, createdName=cement123, createdTime=Thu May 21 13:33:00 CST 2015, time=2015-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1370825, encodeId=b6b513e0825ad, content=<a href='/topic/show?id=9c39864991e' target=_blank style='color:#2F92EE;'>#致癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86499, encryptionId=9c39864991e, topicName=致癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c25323, createdName=jambiya, createdTime=Wed May 20 13:55:00 CST 2015, time=2015-05-20, status=1, ipAttribution=)]
    2015-10-26 minlingfeng
  3. [GetPortalCommentsPageByObjectIdResponse(id=1820320, encodeId=fb57182032095, content=<a href='/topic/show?id=c6fb1006e830' target=_blank style='color:#2F92EE;'>#颊粘膜拭子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100678, encryptionId=c6fb1006e830, topicName=颊粘膜拭子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69cb413, createdName=chengjn, createdTime=Sat Jul 11 14:55:00 CST 2015, time=2015-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864660, encodeId=c3b118646601c, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Oct 26 22:55:00 CST 2015, time=2015-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1690947, encodeId=4855169094e4f, content=<a href='/topic/show?id=7adce62603e' target=_blank style='color:#2F92EE;'>#粘膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76260, encryptionId=7adce62603e, topicName=粘膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=090129165428, createdName=guoyibin, createdTime=Mon Nov 09 20:55:00 CST 2015, time=2015-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1674368, encodeId=54f416e43680a, content=<a href='/topic/show?id=e8aa13359b1' target=_blank style='color:#2F92EE;'>#Oncology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13359, encryptionId=e8aa13359b1, topicName=Oncology)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb7226973259, createdName=circumcision, createdTime=Sun Aug 30 00:55:00 CST 2015, time=2015-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=24418, encodeId=6b91244187d, content=这么厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b64e106775, createdName=cement123, createdTime=Thu May 21 13:33:00 CST 2015, time=2015-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1370825, encodeId=b6b513e0825ad, content=<a href='/topic/show?id=9c39864991e' target=_blank style='color:#2F92EE;'>#致癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86499, encryptionId=9c39864991e, topicName=致癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c25323, createdName=jambiya, createdTime=Wed May 20 13:55:00 CST 2015, time=2015-05-20, status=1, ipAttribution=)]
    2015-11-09 guoyibin
  4. [GetPortalCommentsPageByObjectIdResponse(id=1820320, encodeId=fb57182032095, content=<a href='/topic/show?id=c6fb1006e830' target=_blank style='color:#2F92EE;'>#颊粘膜拭子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100678, encryptionId=c6fb1006e830, topicName=颊粘膜拭子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69cb413, createdName=chengjn, createdTime=Sat Jul 11 14:55:00 CST 2015, time=2015-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864660, encodeId=c3b118646601c, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Oct 26 22:55:00 CST 2015, time=2015-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1690947, encodeId=4855169094e4f, content=<a href='/topic/show?id=7adce62603e' target=_blank style='color:#2F92EE;'>#粘膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76260, encryptionId=7adce62603e, topicName=粘膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=090129165428, createdName=guoyibin, createdTime=Mon Nov 09 20:55:00 CST 2015, time=2015-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1674368, encodeId=54f416e43680a, content=<a href='/topic/show?id=e8aa13359b1' target=_blank style='color:#2F92EE;'>#Oncology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13359, encryptionId=e8aa13359b1, topicName=Oncology)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb7226973259, createdName=circumcision, createdTime=Sun Aug 30 00:55:00 CST 2015, time=2015-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=24418, encodeId=6b91244187d, content=这么厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b64e106775, createdName=cement123, createdTime=Thu May 21 13:33:00 CST 2015, time=2015-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1370825, encodeId=b6b513e0825ad, content=<a href='/topic/show?id=9c39864991e' target=_blank style='color:#2F92EE;'>#致癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86499, encryptionId=9c39864991e, topicName=致癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c25323, createdName=jambiya, createdTime=Wed May 20 13:55:00 CST 2015, time=2015-05-20, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1820320, encodeId=fb57182032095, content=<a href='/topic/show?id=c6fb1006e830' target=_blank style='color:#2F92EE;'>#颊粘膜拭子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100678, encryptionId=c6fb1006e830, topicName=颊粘膜拭子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69cb413, createdName=chengjn, createdTime=Sat Jul 11 14:55:00 CST 2015, time=2015-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864660, encodeId=c3b118646601c, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Oct 26 22:55:00 CST 2015, time=2015-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1690947, encodeId=4855169094e4f, content=<a href='/topic/show?id=7adce62603e' target=_blank style='color:#2F92EE;'>#粘膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76260, encryptionId=7adce62603e, topicName=粘膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=090129165428, createdName=guoyibin, createdTime=Mon Nov 09 20:55:00 CST 2015, time=2015-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1674368, encodeId=54f416e43680a, content=<a href='/topic/show?id=e8aa13359b1' target=_blank style='color:#2F92EE;'>#Oncology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13359, encryptionId=e8aa13359b1, topicName=Oncology)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb7226973259, createdName=circumcision, createdTime=Sun Aug 30 00:55:00 CST 2015, time=2015-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=24418, encodeId=6b91244187d, content=这么厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b64e106775, createdName=cement123, createdTime=Thu May 21 13:33:00 CST 2015, time=2015-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1370825, encodeId=b6b513e0825ad, content=<a href='/topic/show?id=9c39864991e' target=_blank style='color:#2F92EE;'>#致癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86499, encryptionId=9c39864991e, topicName=致癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c25323, createdName=jambiya, createdTime=Wed May 20 13:55:00 CST 2015, time=2015-05-20, status=1, ipAttribution=)]
    2015-05-21 cement123

    这么厉害

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1820320, encodeId=fb57182032095, content=<a href='/topic/show?id=c6fb1006e830' target=_blank style='color:#2F92EE;'>#颊粘膜拭子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100678, encryptionId=c6fb1006e830, topicName=颊粘膜拭子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69cb413, createdName=chengjn, createdTime=Sat Jul 11 14:55:00 CST 2015, time=2015-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864660, encodeId=c3b118646601c, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Oct 26 22:55:00 CST 2015, time=2015-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1690947, encodeId=4855169094e4f, content=<a href='/topic/show?id=7adce62603e' target=_blank style='color:#2F92EE;'>#粘膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76260, encryptionId=7adce62603e, topicName=粘膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=090129165428, createdName=guoyibin, createdTime=Mon Nov 09 20:55:00 CST 2015, time=2015-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1674368, encodeId=54f416e43680a, content=<a href='/topic/show?id=e8aa13359b1' target=_blank style='color:#2F92EE;'>#Oncology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13359, encryptionId=e8aa13359b1, topicName=Oncology)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb7226973259, createdName=circumcision, createdTime=Sun Aug 30 00:55:00 CST 2015, time=2015-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=24418, encodeId=6b91244187d, content=这么厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b64e106775, createdName=cement123, createdTime=Thu May 21 13:33:00 CST 2015, time=2015-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1370825, encodeId=b6b513e0825ad, content=<a href='/topic/show?id=9c39864991e' target=_blank style='color:#2F92EE;'>#致癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86499, encryptionId=9c39864991e, topicName=致癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c25323, createdName=jambiya, createdTime=Wed May 20 13:55:00 CST 2015, time=2015-05-20, status=1, ipAttribution=)]
    2015-05-20 jambiya

相关资讯

The Lancet:2型糖尿病患者戒烟后风险更高?

    吸烟会增加患2型糖尿病的风险。然而,一些人口研究还表明,吸烟者戒烟3 - 5年后比继续吸烟者风险更高。经过10 - 12年的风险等同于从不吸烟者。小型队列研究表明,糖尿病患者控制在戒烟后的第一年暂时恶化。我们在一项人口研究中检测戒烟是否与糖尿病控制相关联,这种关联多久持续存在,并且这种关联是否是由重量变化介导的。    为此,我们使用健康促进网络(T

J Am Dent Assoc:吸烟可影响牙齿漂白的远期效果

近几年,公众对牙齿的审美需求逐步提高,其中包括牙齿漂白。多项临床研究报道了10%过氧化脲(CP)家庭内漂白的效果。本研究的研究人员进行了一项两中心对照临床试验,显示吸烟和非吸烟者家庭内漂白的第一周和第一个月时的效果对比,并评估了牙齿敏感(TS)的严重程度。该研究纳入了60名吸烟者,60名非吸烟者,研究对

J Periodont Res:牙周洁治后辅助使用甲硝唑有用吗?

J Periodont Res:牙周洁治后辅助使用甲硝唑有用吗?关键词:牙周辅助性治疗   甲硝唑  牙周炎  吸烟慢性牙周炎患者的牙周治疗程序中,甲硝唑是否可作为一种辅助治疗措施的有效证据并不充分。该项试验的目的是为了评估甲硝唑(凝胶用于局部应用,药片用于系统治疗)作为一种慢性牙周炎吸烟患者全口牙周洁治(超声洁治去除牙结石/牙菌斑)后的辅助性治疗的效果。研

JCO:吸烟增加结直肠癌的死亡率

吸烟与结直肠癌患病风险有关,但是吸烟与被诊断为结直肠癌后患者的存活率尚不清楚。我们调查并研究吸烟、诊断前后和结直肠癌患者的死亡率之间的关系。 从最初的结直肠癌年轻患者中,在(1992或1993年)和2009年基线时,我们确认了2,548名新的患有侵袭性、非转移性的结直肠癌患者。吸烟者填写调查问卷,此问卷更新于1997年,以后每2年更新一次。我们得到2258名患者(88.5%)诊断前吸烟信息。

J Addict Med:怀孕期间吸烟对胎儿和产妇健康的不利影响

介绍:可以通过产前教育的目的达到对怀孕期间吸烟不利影响知识空白的了解。方法:这是一个从2011年4月6日至2011年5月25日患者进行首次产前护理横断面调查研究。入选标准包括流利的英语和完成至少75%的问卷。调查包括人口统计信息和4个部分的评估 (1)关于吸烟影响的一般知识 (2)与吸烟关联的癌症风险 (3)吸烟导致的孕产妇和胎儿并发症 (4)长期吸烟对后代

吸烟与肺癌的关系

丹麦流传着一种说法,一户人家屋檐上的鹳巢数量与这家人所生孩子的数量存在着相关性。婴儿是鹳鸟送来的古老传说是真的吗?当然不是。相关性跟因果关系不是一回事。鹳不会送来孩子,但大房子有更大的空间为孩子和鹳所用。这是一则人们喜闻乐见的统计趣闻,但如果你知道1965年在美国参议院一场听证会上它是如何被用到的,你就不会觉得那么有趣了。那位做听证发言的专家证人辩称,尽管吸烟或许跟肺癌相关,但两者之间不存在已